Table I.
Correlation of FMO5 expression with clinico-pathological characteristics of colon cancer.
| TMA | TCGA | ||||||
|---|---|---|---|---|---|---|---|
| Clinical features | Case | Low, n (%) | High, n (%) | P-value | Case | Mean ± SD | P-value |
| Tissue | |||||||
| Cancer | 208 | 44 (21.2) | 164 (78.8) | <0.001 | 192 | 297.70±218.89 | – |
| Normal | 8 | 7 (87.5) | 1 (12.5) | – | |||
| Age (years) | |||||||
| <25 | 2 | 10 (37.0) | 17 (63.0) | 0.015 | 0 | – | 0.529 |
| 25–40 | 27 | 23 (22.6) | 70 (77.4) | 3 | 204.00±26.47 | ||
| 41–60 | 93 | 10 (11.6) | 76 (88.4) | 38 | 52.36±205.20 | ||
| >60 | 86 | 10 (37.0) | 17 (63.0) | 151 | 306.00±224.02 | ||
| Sex | |||||||
| Male | 118 | 23 (19.5) | 95 (80.5) | 0.501 | 94 | 288.88±213.95 | 0.586 |
| Female | 90 | 21 (23.3) | 69 (76.7) | 98 | 306.16±224.30 | ||
| Pathological grade | |||||||
| ≤2 | 150 | 26 (17.3) | 124 (82.7) | 0.090 | – | – | – |
| >2 | 41 | 12 (29.3) | 29 (70.7) | – | – | – | |
| Clinical stage | |||||||
| I–II | 150 | 38 (25.3) | 112 (74.7) | 0.018 | 108 | 326.62±246.68 | 0.047 |
| III–IV | 58 | 6 (10.3) | 52 (89.7) | 81 | 262.37±173.24 | ||
| Tumor invasion | |||||||
| T1-T2 | 23 | 4 (17.4) | 19 (82.6) | 0.790 | 172 | 298.73±256.84 | 0.988 |
| T3-T4 | 185 | 40 (21.6) | 145 (78.4) | 4 | 298.15±208.42 | ||
| Lymph node metastasis | |||||||
| N0 | 153 | 38 (24.8) | 115 (75.2) | 0.030 | 114 | 324.77±242.47 | 0.045 |
| N1–2 | 55 | 6 (10.9) | 49 (89.1) | 77 | 260.16±173.12 | ||
| Distant metastasis | |||||||
| M0 | 197 | 44 (22.3) | 153 (77.7) | 0.125 | 158 | 313.67±230.88 | 0.030 |
| M1 | 11 | 0 (0.0) | 11 (100.0) | 30 | 218.50±131.43 | ||
−, indicates a lack of related information for the patient. The pathological grade of 17 CRC patients from TCGA were unavailable. FMO5, flavin-containing monooxygenase 5; TMA, tissue microarray; TCGA, The Cancer Genome Atlas.